Specialised Units

Patients area

24-hour Emergency Cancer Care

Consultants

Genomic platform

Through genomic tests we can know the behavior of certain groups of genes against cancer, their level of activity including the probability of growing or spreading, this helps us to customize the treatment of each patient. It is done by a simple blood test or by a biopsy on the same tumor or tumor tissue that was resected.

There is also the possibility of being able to perform a genetic test that indicates whether there is an anomalous alteration (also called mutation) with a gene that may be linked to an increased risk of developing a breast cancer in the future.

Genetic tests

• BRCA I and BCRA II: Genetic test to determine the hereditary risk of hereditary breast and ovarian cancer, facilitating follow-up and preventive activities.

 

Determination of Microsatellite Instability and alterations in DNA Repair Proteins (MMR). Test performed on a tumor piece to determine the risk of hereditary colorectal cancer and family syndromes such as Lynch syndrome. In addition, this instability leads to the sensitivity of tumors to treatment with immunotherapy.

Genomic tests

• FoundationOne® Test for mutational characterization and search for therapeutic targets for solid tumors in a tumor biopsy sample. It allows a search of therapies directed on the alterations found.

 

• Foundation One Heme® Test for mutational characterization and search for therapeutic targets for tumors of hematological origin, sarcomas and some pediatric tumors.

 

• Foundation ACT® Test for genetic diagnosis on blood sample (Liquid Biopsy) when there is no tumor tissue available, mutational sequencing and therapeutic targets. In tumors with lack of sufficient biological sample it allows a search of targeted therapies on the alterations found.

 

• MammaPrint®, mutational sequencing in early stage breast cancer to safely determine the risk of relapse and the need or not of treatment with chemotherapy.

 

• Oncotype DX®– mutational sequencing in early stage breast cancer to safely determine the risk of relapse and the need or not of treatment with chemotherapy.

 

• Prosigna® mutational sequencing in early stage breast cancer to safely determine the risk of relapse and the need or not of treatment with chemotherapy.

 

• EPICUP® genomic test indicated to know the probable origin of a primary tumor of unknown origin.

 

• OncotypeDX Colon Recurrence Score®: Mutation sequencing in early colon cancer to safely determine the risk of relapse and the need or not of treatment with chemotherapy.

 

• ONCODEEP TM: Test for mutational characterization and search for targeted therapeutic targets for solid tumors in a tumor biopsy sample. It allows the search of targeted therapies on the alterations found.